口服JAK1抑制剂povorcitinib治疗广泛性白癜风的2期随机双盲剂量探索安慰剂对照研究
该2期研究将171例广泛性非节段性白癜风成人患者按1:1:1:1随机分配至povorcitinib 15、45、75 mg或安慰剂组治疗24周,主要终点为第24周T-VASI较基线变化百分比。结果显示各剂量组T-VASI均显著优于安慰剂(P<.01),且改善持续至第52周,安全性和耐受性良好。
要点
- povorcitinib 15、45、75 mg组第24周T-VASI较基线改善均显著优于安慰剂(P<.01)。
- 连续治疗至第52周可观察到持续复色改善。
- ≥3级治疗中出现的不良事件发生率各组相似,未见新安全性信号。
核心结论
- povorcitinib在广泛性非节段性白癜风成人患者中显示出显著的全身和面部复色效果,且至52周治疗总体耐受良好。
研究设计与样本
- 双盲、安慰剂对照、剂量探索的2期研究(NCT04818346),将171例成人患者按1:1:1:1随机分配至povorcitinib 15、45、75 mg或安慰剂每日一次治疗24周。
- 随后患者接受povorcitinib 45 mg(初随机为45 mg者)或75 mg(初随机为安慰剂、15或75 mg者)治疗至第52周,并随访24周。
- 主要终点为第24周总白癜风面积评分指数(T-VASI)较基线的变化百分比。
主要发现
- 171例患者平均总体表面积/T-VASI为28.2%/25.5,82.5%完成24周治疗。
- 第24周时,povorcitinib显著改善T-VASI(15 mg组19.1%;45 mg组17.8%;75 mg组15.7%),安慰剂组为-2.3%(最小二乘均值比较,P<.01)。
- 至第52周观察到持续改善。
- ≥3级治疗中出现的不良事件发生率在各治疗组间相似,未见新安全性信号。
关键数值与推荐
- 第24周T-VASI较基线变化百分比:povorcitinib 15 mg组19.1%,45 mg组17.8%,75 mg组15.7%,安慰剂组-2.3%(P<.01)。
临床怎么用
- 对于影响>10%体表面积的广泛性非节段性白癜风,口服povorcitinib可能提供一种有效的复色治疗选择。
- 治疗需持续至52周以观察持续改善,并注意监测不良事件。
局限性
- 人口统计学多样性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No repigmentation treatments are approved for vitiligo affecting > 10% body surface area. OBJECTIVE: To assess efficacy and safety of povorcitinib (oral, selective Janus kinase 1 inhibitor) in extensive nonsegmental vitiligo. METHODS: This double-blinded, placebo-controlled, dose-ranging phase 2 study (NCT04818346) randomized adult patients 1:1:1:1 to once-daily povorcitinib 15, 45, or 75 mg or placebo for 24 weeks. Subsequently, patients received povorcitinib 45 mg (initially randomized to 45 mg) or 75 mg (initially randomized to placebo, 15, or 75 mg) until week 52, followed by 24-week post-treatment follow-up. Primary endpoint was percentage change from baseline in total Vitiligo Area Scoring Index (T-VASI) at week 24. RESULTS: Of 171 patients (mean total body surface area/T-VASI, 28.2%/25.5) randomized, 82.5% completed the 24-week treatment. At week 24, povorcitinib significantly improved T-VASI from baseline (15 mg, 19.1%; 45 mg, 17.8%; 75 mg, 15.7%) versus placebo (-2.3%; least squares mean povorcitinib vs placebo, P < .01). Continuous improvement was observed through week 52. Incidence of grade ≥ 3 treatment-emergent adverse events was similar across treatment groups, with no new safety signals. LIMITATIONS: Limited demographic diversity. CONCLUSION: Povorcitinib demonstrated substantial total body and facial repigmentation in adult patients with extensive nonsegmental vitiligo and was generally well tolerated through 52 weeks of treatment.
引用
- Pandya AG, Ezzedine K, Passeron T, et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study. J Am Acad Dermatol. 2025. PMID: 40518122. doi:10.1016/j.jaad.2025.06.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。